The ultimate goal of this multicenter, phase II study is to increase blood pressure until
either a neurologic response is seen or a target mean arterial pressure of 30% above baseline
is achieved. IV fluids, IV phenylephrine and/or IV norepinephrine are used to rapidly raise
mean arterial pressure in a controlled manner as serial assessments of neurologic function
are performed.